Medline ® Abstract for Reference 53
of 'Systemic treatment of metastatic breast cancer in women: Chemotherapy'
Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer.
Falkson G, Tormey DC, Carey P, Witte R, Falkson HC
Eur J Cancer. 1991;27(8):973.
Long-term survival of patients with metastatic breast cancer treated on two prospective stratified randomised trials has been analysed. Patients on study B122 received either cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or cyclophosphamide, doxorubicin and 5-fluorouracil (CAF). On study B141 patients received CAF or mitolactol (dibromodulcitol), doxorubicin and vincristine alternating after every three cycles with three cycles of CMF (DAV/CMF). Long-term follow-up of 172 patients showed no significant survival difference (in multivariate regression models) for treatment with either CMF vs. CAF or CAF vs. DAV/CMF. The difference in median survival times between CMF and CAF showed a trend in favour of CAF. Advances in the management of metastatic breast cancer in postmenopausal women obtained by doxorubicin regimens have had a small but measurable impact on survival, but known patient discriminants were not overridden by the treatment regimens investigated in these studies.
Department of Medical Oncology, University of Pretoria, Republic of South Africa.